NASDAQ · Biotechnology

Innoviva, Inc. (INVA) Stock

$20.78 -0.38% NASDAQ: INVA Healthcare

Valuation

MetricValue
Price$20.78
Market Cap$1.50B
P/E Ratio4.21
P/B Ratio1.22
P/S Ratio3.41
EPS (TTM)$3.30
52-Week High$25.15
52-Week Low$16.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE30.03%
ROA20.98%
ROCE9.82%
Gross Margin76.20%
Operating Margin14.85%
Net Margin80.56%
Debt/Equity0.22
Current Ratio14.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$392.0M$331.0M$310.0M$359.0M$425.0M
Operating Profit$375.0M$207.0M$114.0M$167.0M$164.0M
Net Profit$266.0M$214.0M$180.0M$23.0M$271.0M
EPS$2.87$2.37$2.20$0.36$3.30
Op Margin95.7%62.5%36.7%46.5%38.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$926.0M$1.2B$1.2B$1.3B$1.6B
Total Liabilities$400.0M$666.0M$569.0M$610.0M$462.0M
Cash$202.0M$291.0M$194.0M$305.0M$551.0M
Borrowings$395.0M$544.0M$449.0M$451.0M$269.0M

Latest News

INVA: What does Argus have to say about INVA? Argus Research · Jul 15, 2026 Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now? Insider Monkey · Jul 1, 2026 Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform Insider Monkey · Jun 25, 2026 Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally Insider Monkey · Jun 23, 2026 Nortiva Bio Launches to Develop Long-Acting Oral Medicines Business Wire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$364.0M$202.0M$141.0M$189.0M$197.0M
Investing Cash Flow$42.0M$-57.0M$-67.0M$-64.0M$30.0M
Financing Cash Flow$-454.0M$-122.0M$-76.0M$-15.0M$-5.0M
Net Cash Flow$-45.0M$90.0M$-98.0M$111.0M$246.0M
Free Cash Flow$363.0M$202.0M$141.0M$188.0M$186.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA1.47
FCF Yield12.45%
Quick Ratio15.18
Interest Coverage8.92
Return 1Y9.96%
Return 3Y60.36%
Return 5Y66.08%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
TBPH $17.03 +0.00% 16.05 $882.64M 0.00%

About Innoviva, Inc.

Innoviva, Inc. is led by CEO Pavel Raifeld, employs 127 people, headquartered in US, publicly traded since 2004.

Innoviva, Inc. (INVA) stock trades at $20.78 with a market capitalization of $1.50B. The stock is valued at a price-to-earnings (P/E) ratio of 4.21, price-to-book of 1.22, price-to-sales of 3.41. Over the past 52 weeks the stock has ranged between $16.52 and $25.15, and currently trades 17.4% below its 52-week high.

On profitability, Innoviva, Inc. generates a return on equity (ROE) of 30.03%, above the typical market range of roughly 12-15%, return on capital employed of 9.82%, an operating margin of 14.85%, a net profit margin of 80.56%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.